CHANDY RUBY R 4

What Happened

• Ruby R. Chandy, a director of Thermo Fisher Scientific (TMO), was granted 499 shares on May 20, 2026. The Form 4 reports the grant as an acquisition at $0.00 per share, indicating these were awarded shares (e.g., restricted stock or similar compensation), not a market purchase.

Key Details

• Transaction date: May 20, 2026; Form 4 filed May 22, 2026 (appears timely under standard Form 4 rules).
• Transaction type: Award/Grant (reported as acquisition at $0.00).
• Shares involved: 499 shares acquired.
• Shares owned after the transaction: not specified in the filing.
• Notable exhibits/footnotes: Exhibit 24 (Power of Attorney) is attached; no 10b5-1 plan, tax withholding, or sale noted in this filing.

Context

• Awards (grants) are typically part of compensation or director equity programs and do not necessarily signal the insider buying or selling for investment reasons. Because the shares are reported at $0.00, this reflects an award rather than a cash purchase.